GlassScriptPhysician profile
Bibas Reddy
NPI 1457577017
$23,826.35
in general payments reported to CMS, 2019-2025
62 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $2,542 · 2021: $1,607 · 2022: $335 · 2023: $6,033 · 2024: $1,975 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,609 · Food and Beverage: $6,335 · Honoraria: $4,550 · Education: $92.98 · Travel and Lodging: $70.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,609.00 |
| Food and Beverage | $6,334.96 |
| Honoraria | $4,550.00 |
| Education | $92.98 |
| Travel and Lodging | $70.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $4,693.24 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $4,009.51 | 2020-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Scientific Affairs, LLC | $3,248.14 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $2,727.03 | 2024-2025 | Libtayo |
| Regeneron Healthcare Solutions, INC. | $2,028.90 | 2024-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $380.94 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Puma Biotechnology, INC. | $368.50 | 2019-2023 | |
| Intuitive Surgical, INC. | $328.50 | 2023-2024 | |
| Janssen Biotech, INC. | $322.42 | 2019-2025 | Rybrevant, Erleada |
| Daiichi Sankyo INC. | $308.17 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $296.70 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $291.83 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Celgene Corporation | $290.74 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $281.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.96 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $207.46 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $193.12 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $178.79 | 2020-2025 | Jaypirca, Verzenio |
| Eisai INC. | $176.79 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $175.78 | 2024-2025 | |
| Melinta Therapeutics, LLC | $169.45 | 2024-2025 | Rezzayo, Vabomere, Kimyrsa |
| Sirtex Medical INC | $168.68 | 2023 | Sir-Spheres Microspheres |
| Stemline Therapeutics INC. | $162.72 | 2023-2024 | Orserdu |
| Caris Mpi, INC. | $159.98 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $157.13 | 2024-2025 | Xtandi, Padcev |
| Incyte Corporation | $149.83 | 2023-2025 | Jakafi, Monjuvi |
| Gilead Sciences, INC. | $145.24 | 2023-2025 | Trodelvy |
| Foundation Medicine, INC. | $144.29 | 2023 | |
| Blueprint Medicines Corporation | $140.77 | 2024-2025 | Ayvakit |
| Monteris Medical Corporation | $134.65 | 2022 | |
| Array Biopharma INC | $97.84 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Tolmar, INC. | $79.40 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $79.40 | 2025 | Rubraca |
| Teva Pharmaceuticals USA, INC. | $79.31 | 2019 | |
| Genmab U.S., INC. | $78.69 | 2024-2025 | Tivdak, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $77.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.87 | 2024-2025 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $73.54 | 2023-2024 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $67.45 | 2025 | Besremi |
| Fennec Pharmaceuticals, INC. | $66.00 | 2025 | Fyarro |
| Sanofi-Aventis U.S. LLC | $64.99 | 2020 | |
| Pfizer INC. | $59.86 | 2024-2025 | |
| Tersera Therapeutics LLC | $55.53 | 2025 | Quzyttir, Zoladex |
| Emd Serono, INC. | $53.31 | 2025 | |
| Tg Therapeutics, INC. | $49.99 | 2021 | |
| Kite Pharma, INC. | $49.51 | 2024 | Yescarta |
| Servier Pharmaceuticals LLC | $49.18 | 2025 | |
| Genzyme Corporation | $41.30 | 2019-2025 | |
| Amgen INC. | $40.90 | 2019 | |
| Epizyme, INC. | $30.58 | 2021 | |
| Dendreon Pharmaceuticals LLC | $29.41 | 2025 | Provenge |
| Springworks Therapeutics, INC. | $27.93 | 2025 | Ogsiveo |
| Karyopharm Therapeutics INC. | $27.28 | 2024 | Xpovio |
| Acrotech Biopharma INC. | $25.90 | 2021 | |
| Coherus Oncology, INC. | $24.98 | 2025 | Loqtorzi |
| Beone Medicines USA, INC. | $19.36 | 2025 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $16.67 | 2025 | Rolvedon |
| Sobi, INC | $16.17 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $15.34 | 2023 | Sancuso |
| Menarini Silicon Biosystems, INC. | $14.84 | 2023 | Cellsearch |
| Pharmacosmos Therapeutics INC. | $14.72 | 2025 | Monoferric |
| Morphosys, US INC. | $14.26 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bibas Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.